PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer

Stock Information for PDS Biotechnology Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PDS Biotechnology Corporation

PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
PDS Biotechnology Announces Details of Virtual KOL Event
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.